Consistent with these findings on a cellular level, a number of recent studies have implicated PSMA6 polymorphisms are associated with the development of coronary artery disease [15, 16], myocardial infarction, and ischemic stroke [17], as well as a cluster of clinical disorders (e.g., hypertension, central obesity, dyslipidemia, and insulin resistance) in patients with T2DM [18]. This evidence concerns the gene PSMA6 and coronary artery disorder.